Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
The FDA accepted Karyopharm's supplemental New Drug Application for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, with a PDUFA target action date of June 28, 2027. The filing is based primarily on the Phase 3 SENTRY trial (N=353), and if approved the combination could become the first approved therapy for myelofibrosis beyond JAK inhibitors.
Key figures
- Drug Name
- XPOVIO (selinexor)
- Phase Of Trial
- Phase 3
- Pdufa date
- June 28, 2027
- Trial name
- SENTRY (XPORT-MF-034; NCT04562389)
- Trial enrollment
- N=353
- Chapter11 expected close
- Q1 2027
- Eu myelofibrosis patients
- 19000
- Us myelofibrosis patients
- 20000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.